CO6260015A2 - Metodos y tratamiento para la dependencia, mediante la administracion de un agente psicoestimulante, un opiode y otros - Google Patents

Metodos y tratamiento para la dependencia, mediante la administracion de un agente psicoestimulante, un opiode y otros

Info

Publication number
CO6260015A2
CO6260015A2 CO10023191A CO10023191A CO6260015A2 CO 6260015 A2 CO6260015 A2 CO 6260015A2 CO 10023191 A CO10023191 A CO 10023191A CO 10023191 A CO10023191 A CO 10023191A CO 6260015 A2 CO6260015 A2 CO 6260015A2
Authority
CO
Colombia
Prior art keywords
methods
dependence
opiode
psychostimulating
administration
Prior art date
Application number
CO10023191A
Other languages
English (en)
Spanish (es)
Inventor
Tom Woiwode
Mark Moran
Lesley Pickford
Original Assignee
Synosia Therapeutics
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Synosia Therapeutics filed Critical Synosia Therapeutics
Publication of CO6260015A2 publication Critical patent/CO6260015A2/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/417—Imidazole-alkylamines, e.g. histamine, phentolamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A61P25/12—Antiepileptics; Anticonvulsants for grand-mal
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32—Alcohol-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/34—Tobacco-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/36—Opioid-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/06—Antiarrhythmics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Epidemiology (AREA)
  • Addiction (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Pulmonology (AREA)
  • Hospice & Palliative Care (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Otolaryngology (AREA)
  • Anesthesiology (AREA)
  • Urology & Nephrology (AREA)
  • Psychology (AREA)
  • Vascular Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
CO10023191A 2007-08-06 2010-02-26 Metodos y tratamiento para la dependencia, mediante la administracion de un agente psicoestimulante, un opiode y otros CO6260015A2 (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US93532307P 2007-08-06 2007-08-06
US95655507P 2007-08-17 2007-08-17
US96059107P 2007-10-04 2007-10-04

Publications (1)

Publication Number Publication Date
CO6260015A2 true CO6260015A2 (es) 2011-03-22

Family

ID=40341713

Family Applications (1)

Application Number Title Priority Date Filing Date
CO10023191A CO6260015A2 (es) 2007-08-06 2010-02-26 Metodos y tratamiento para la dependencia, mediante la administracion de un agente psicoestimulante, un opiode y otros

Country Status (16)

Country Link
US (3) US20090041800A1 (OSRAM)
EP (2) EP3251670A1 (OSRAM)
JP (5) JP2010535801A (OSRAM)
CN (2) CN101815438A (OSRAM)
AU (1) AU2008283903B2 (OSRAM)
BR (1) BRPI0815089A2 (OSRAM)
CA (1) CA2695372C (OSRAM)
CO (1) CO6260015A2 (OSRAM)
ES (1) ES2638190T3 (OSRAM)
IL (1) IL257418A (OSRAM)
MX (4) MX391921B (OSRAM)
NZ (1) NZ583192A (OSRAM)
PH (1) PH12015502210A1 (OSRAM)
RU (1) RU2491067C2 (OSRAM)
SG (2) SG10201705968RA (OSRAM)
WO (1) WO2009021055A1 (OSRAM)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2008283903B2 (en) 2007-08-06 2014-01-16 Biotie Therapies, Inc Methods for treating dependence
WO2010124089A2 (en) * 2009-04-22 2010-10-28 Synosia Therapeutics, Inc. Methods for treating dependence
US9804149B2 (en) * 2012-10-10 2017-10-31 Bio-Rad Laboratories, Inc. Patient-based results display
WO2015023675A2 (en) 2013-08-12 2015-02-19 Pharmaceutical Manufacturing Research Services, Inc. Extruded immediate release abuse deterrent pill
US10172797B2 (en) 2013-12-17 2019-01-08 Pharmaceutical Manufacturing Research Services, Inc. Extruded extended release abuse deterrent pill
US9492444B2 (en) 2013-12-17 2016-11-15 Pharmaceutical Manufacturing Research Services, Inc. Extruded extended release abuse deterrent pill
US9192570B2 (en) 2013-12-20 2015-11-24 AntiOP, Inc. Intranasal naloxone compositions and methods of making and using same
AU2015290098B2 (en) 2014-07-17 2018-11-01 Pharmaceutical Manufacturing Research Services, Inc. Immediate release abuse deterrent liquid fill dosage form
AU2015336065A1 (en) 2014-10-20 2017-05-04 Pharmaceutical Manufacturing Research Services, Inc. Extended release abuse deterrent liquid fill dosage form
US20170235908A1 (en) * 2015-11-15 2017-08-17 Oriah Behaviorial Health, Inc. Systems and Methods for Managing and Treating Substance Abuse Addiction
US11844859B2 (en) 2017-08-20 2023-12-19 Nasus Pharma Ltd. Dry powder compositions for intranasal delivery
JP7334145B2 (ja) 2017-08-20 2023-08-28 ネイサス ファーマ リミテッド 鼻腔内送達用乾燥粉末組成物
US12459965B2 (en) 2017-10-09 2025-11-04 Compass Pathfinder Limited Preparation of psilocybin, different polymorphic forms, intermediates, formulations and their use
GB2571696B (en) 2017-10-09 2020-05-27 Compass Pathways Ltd Large scale method for the preparation of Psilocybin and formulations of Psilocybin so produced
CN108066355A (zh) * 2017-12-28 2018-05-25 宁夏恩多芬科技有限公司 Nitrous Oxide作为治疗神经官能症的用途
FR3093419B1 (fr) * 2019-03-08 2021-06-18 Univ Grenoble Alpes Composition et procédé associé de mesure de l’observance thérapeutique
JP2022529353A (ja) 2019-04-17 2022-06-21 コンパス パスファインダー リミテッド 神経認知障害、慢性疼痛を治療し、炎症を低減させる方法
BR112022008919A2 (pt) * 2019-11-07 2022-08-09 Small Pharma Ltd Composto e método para tratamento de distúrbios psiquiátrico ou neurológico
US11806320B2 (en) * 2020-02-19 2023-11-07 Endo Ventures Limited Isoproterenol compositions and methods
CN115667217A (zh) 2020-05-19 2023-01-31 赛本爱尔兰有限公司 氘化的色胺衍生物和使用方法
KR20230071131A (ko) * 2020-08-17 2023-05-23 더 트러스티스 오브 컬럼비아 유니버시티 인 더 시티 오브 뉴욕 도파민 기능의 바이오마커로서 뉴로멜라닌-민감성 mri의 용도
JP7753359B2 (ja) * 2020-10-24 2025-10-14 ユニヴェルシテートスピタル バーゼル ヒト血漿中のリゼルギン酸ジエチルアミド（ｌｓｄ）及び２，３－ジヒドロ－３－ヒドロキシ－２－オキソリセルギド（ｏ－ｈ－ｌｓｄ）を定量化するための方法
US12029718B2 (en) 2021-11-09 2024-07-09 Cct Sciences, Llc Process for production of essentially pure delta-9-tetrahydrocannabinol
CN112690771B (zh) * 2020-12-09 2022-05-24 华南理工大学 一种利用线性回归模型的人脸视频心率检测方法
KR20230156903A (ko) 2021-03-11 2023-11-15 테란 바이오사이언시스 인코포레이티드 바이오마커를 포함하는 영상 데이터세트의 조화를 위한 시스템, 디바이스 및 방법
CN113017632B (zh) * 2021-03-17 2022-11-11 陈思 一种智慧校园心理咨询辅助方法及系统
WO2023168022A1 (en) 2022-03-04 2023-09-07 Reset Pharmaceuticals, Inc. Co-crystals or salts comprising psilocybin
CN119487007A (zh) 2022-09-16 2025-02-18 江苏亚虹医药科技股份有限公司 内匹司他酸加成盐的多晶型及其制备方法和用途
WO2024178082A2 (en) * 2023-02-22 2024-08-29 Freedom Biosciences, Inc. Composition of opioid receptor modulator and mdma for use thereof
CN120754106B (zh) * 2025-09-02 2025-12-09 合肥工业大学 化合物sch23390在制备治疗铅中毒药物中的应用

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0381696B1 (en) * 1987-10-07 1993-07-28 Matrix Technologies, Inc. Pharmaceutical composition for the treatment of cocaine addiction
US5593367A (en) * 1995-08-18 1997-01-14 Deere & Company Switchable ignition and starter control system
AU2131697A (en) * 1996-02-23 1997-09-10 Pharm-Eco Laboratories, Incorporated Selective D1 dopamine receptor agonists and partial agonists/antagonist
US5958896A (en) * 1997-08-08 1999-09-28 The Mclean Hospital Cytidine-containing and cytosine-containing compounds as treatments for stimulant exposure
US6541520B1 (en) * 1998-08-05 2003-04-01 Brookhaven Science Associates Treatment of addiction and addiction-related behavior
PT1374952E (pt) * 2001-01-17 2006-12-29 Hythiam Inc Utilização de flumazenil no desenvolvimento de um fármaco para o tratamento da dependência do alcoól
AU2002245613A1 (en) * 2001-03-07 2002-09-24 The Mclean Hospital Corporation Methods and reagents for identifying compounds and mutations that modulate dopamine beta-hydroxylase activity
SE0104388D0 (sv) * 2001-12-27 2001-12-27 Pharmacia Ab New formulation and use and manufacture thereof
ATE487492T1 (de) * 2003-02-27 2010-11-15 Eisai R&D Man Co Ltd Pharmazeutische zusammensetzung zur behandlung von drogenabhängigkeit
RU2252756C1 (ru) * 2003-12-23 2005-05-27 Хохлов Александр Петрович Препарат против алкоголизма и наркомании, способ получения такого препарата
US20100105748A1 (en) * 2007-03-16 2010-04-29 David Weinshenker Methods and compositions for treatment of drug addiction
MX2010000938A (es) * 2007-07-23 2010-07-01 Synosia Therapeutics Inc Uso de (4-metoxi-7-morfolin-4-il-benzotiazol-2-il)-amida del ácido 4-hidroxi-4-metil-piperidin-1-carboxílico para el tratamiento del trastorno por estrés postraumático.
JP2010534676A (ja) * 2007-07-23 2010-11-11 シノシア・セラピューティクス 心的外傷後ストレス障害の治療
WO2009015244A1 (en) * 2007-07-23 2009-01-29 Synosia Therapeutics Rufinamide for the treatment of post-traumatic stress disorder
AU2008283903B2 (en) 2007-08-06 2014-01-16 Biotie Therapies, Inc Methods for treating dependence
US20100243466A1 (en) 2007-11-26 2010-09-30 Bridgestone Corporation Copper-zinc alloy electroplating bath and plating method using the copper-zinc alloy electroplating bath

Also Published As

Publication number Publication date
MX357542B (es) 2018-07-13
MX2010001390A (es) 2010-08-02
EP2182804A1 (en) 2010-05-12
US20090041800A1 (en) 2009-02-12
AU2008283903B2 (en) 2014-01-16
EP2182804B1 (en) 2017-05-24
NZ583192A (en) 2012-06-29
CN101815438A (zh) 2010-08-25
US20200383951A1 (en) 2020-12-10
EP2182804A4 (en) 2010-12-22
JP2020114883A (ja) 2020-07-30
IL257418A (en) 2018-04-30
RU2491067C2 (ru) 2013-08-27
JP2016210798A (ja) 2016-12-15
SG10201705968RA (en) 2017-08-30
EP3251670A1 (en) 2017-12-06
JP2018154645A (ja) 2018-10-04
CA2695372C (en) 2013-01-22
ES2638190T3 (es) 2017-10-19
SG183696A1 (en) 2012-09-27
MX391921B (es) 2025-03-21
US20140099336A1 (en) 2014-04-10
MX2022001510A (es) 2022-08-11
US10561638B2 (en) 2020-02-18
AU2008283903A1 (en) 2009-02-12
JP2014148551A (ja) 2014-08-21
JP2010535801A (ja) 2010-11-25
BRPI0815089A2 (pt) 2014-09-30
CN106983747A (zh) 2017-07-28
CA2695372A1 (en) 2009-02-12
RU2010108249A (ru) 2011-09-20
PH12015502210A1 (en) 2017-04-10
WO2009021055A1 (en) 2009-02-12

Similar Documents

Publication Publication Date Title
CO6260015A2 (es) Metodos y tratamiento para la dependencia, mediante la administracion de un agente psicoestimulante, un opiode y otros
EA202091999A3 (ru) Применение ингибиторов dpp iv
CL2008000606A1 (es) Composicion analgesica en forma de dosificacion parenteral unitaria o en una forma de dosificacion unitaria adecuada para una administracion por la mucosa o la dermis que comprende buprenorfina y naloxona, util para el tratamiento del dolor.
BR112015021861A2 (pt) dispositivo de travamento de acesso de iv - seringa
CL2011000798A1 (es) Uso de etexilato de dabigatran o una sal del mismo para preparar un medicamento util para la prevencion del ictus en pacientes que padecen fibrilacion auricular.
UY31816A (es) Agente para el tratamiento y/o prevención de una enfemedad autoinmune y para la formación de células t reguladoras
WO2010091376A3 (en) Devices and methods for perfusion therapy
MX376937B (es) Metodos para tratar cancer pancreático mediante el uso de terapias de combinacion que comprenden irinotecano liposómico.
UY32177A (es) Tratamiento de diabetes en pacientes con control glucémico insuficiente a pesar de la terapia con fármaco, oral o no, antidiabético
CL2008000608A1 (es) Composicion analgesica en forma de dosificacion parenteral unitaria o en una forma de dosificacion unitaria adecuada para una administracion por la mucosa o la dermis que comprende buprenorfina y naltrexona, util para el tratamiento del dolor.
DOP2013000224A (es) Uso de 2,3-dihidroimidazo[1,2-c] quinazolinas sustituidas.
WO2009073712A3 (en) Medical product management methods
CL2008002999A1 (es) Uso de una composicion farmeceutica que comprende trns-clominefo para preparar un medicamenteo util en el ratamiento de recuccion de los niveles de glucosa en ayunas en un varon.
CL2011000806A1 (es) Uso de etexilato de dabigatran o una sal del mismo para preparar un medicamento util para la prevencion del ictus en pacientes que padecen fibrilacion auricular.
CL2009000803A1 (es) Uso de una variante de igf-1 pegilada para tratar, prevenir un trastorno neuromuscular; metodo para el tratamiento, prevencion y/o demora de un trastorno neuromuscular; composicion que comprende la variante de igf-1 modificada
CY1110182T1 (el) Ιδεβενονη για τη θεραπεια των μυϊκων δυστροφιων
CL2008000607A1 (es) Composicion analgesica en forma de dosificacion parenteral unitaria o en una forma de dosificacion unitaria adecuada para una administracion por la mucosa o la dermis que comprende buprenorfina y nalmefeno, util para el tratamiento del dolor.
AR114148A2 (es) Composición terapéutica saborizada basada en arcilla
WO2005094554A3 (en) Therapeutic agents, methods, and treatments
CO6311083A2 (es) 4-((1r,3s)-6-cloro-3-fenilindan-1-il)-1,2,2-trimetilpiperazina para el tratamiento de la disfunción cognitiva
CL2013000709A1 (es) Composicion que contiene nifurtimox y un antihelmintico seleccionado de: pf1022, emopdepsido, tribendimidina, amidantel, bay d 9216, praziquantel o benzoato de bencilo; util en el tratamiento de enfermedades causadas por giardias (div. sol. 1577-10).
ECSP10010567A (es) Utilizacion de dronedarona para preparar un medicamento para el tratamiento de pacientes con arritmia y que tienen un incremento del nivel de creatinina debido a la administracion de dronedarona
AR056500A1 (es) Metodo para preparar una composicion medica
CL2015001574A1 (es) Terapia combinada para el cancer
ES2325291A1 (es) "uso de un extracto de silybum marianum"

Legal Events

Date Code Title Description
FA Application withdrawn